The Company achieves record net revenue and gross margin results since its inception
CALGARY, AB, Aug. 14, 2023 /PRNewswire/ - SNDL Inc. (NASDAQ: SNDL) ("SNDL" or the "Company") reported its financial and operational results for the second quarter ended June 30, 2023. All financial information in this press release is reported in millions of Canadian dollars unless otherwise indicated.
SNDL has also posted a supplemental investor presentation on its website, which can be found at https://sndl.com.
SECOND QUARTER 2023 FINANCIAL AND OPERATIONAL HIGHLIGHTS
"Our incredible two-year journey from less than $10 million of net revenue and negative gross margin in Q2 2021 to our current trajectory of reaching an expected $1 billion in annual revenue and continued gross margin growth in 2023 is a testament to our team's commitment to becoming a leader in Canadian regulated products," said Zach George, Chief Executive Officer of SNDL. "We have taken decisive steps to simplify operations throughout our business segments with a sharp focus on the goal of reaching profitability in 2024. In Liquor Retail, we are capitalizing on margin accretive product opportunities and modest expansion. In Cannabis Retail, our data licensing program is driving improved profitability and supplier relationships, and we look to enhance consumer engagement through new loyalty capabilities. In our Cannabis Operations, we have taken aggressive cost-cutting measures, streamlined manufacturing operations, and reduced reliance on high-cost cultivation. During this process, we have maintained cannabis sales momentum and are actively exploring B2B and international opportunities. We have also simplified our investment portfolio by divesting from securities, prioritizing the opportunity to return capital to our shareholders."
"Over the last two years, SNDL has grown both organically and by acquisition while our leaders have implemented bold changes throughout the business," added George. "We believe that we now have the requisite scale and platform optionality to create sustainable shareholder value. We expect our Canadian retail network to continue to grow at a modest pace while our internal focus on optimization is in the early stages of producing tangible results. We look forward to updating investors on the closing of the Nova transaction, and events related to our SunStream portfolio as we focus on delivering improved performance in the second half of 2023."
SECOND QUARTER 2023 KEY FINANCIAL METRICS
OPERATING SEGMENTS | ||||||||
($000s) | Liquor | Cannabis | Cannabis | Investments | Corporate | Total | ||
Three months ended June 30, 2023 | ||||||||
Net revenue | 151,690 | 71,881 | 20,940 | ? | ? | 244,511 | ||
Gross margin | 35,360 | 17,780 | (1,207) | ? | ? | 51,933 | ||
Earnings (loss) from Operations | 8,207 | 2,340 | (14,134) | (1,660) | (24,242) | (29,489) | ||
Three months ended June 30, 2022 | ||||||||
Net revenue | 148,637 | 63,494 | 11,564 | ? | ? | 223,695 | ||
Gross margin | 33,528 | 13,897 | (4,346) | ? | ? | 43,079 | ||
Earnings (loss) from Operations | 11,288 | 1,476 | (8,293) | (69,973) | (15,914) | (81,416) |
SECOND QUARTER 2023 RESULTS
SNDL's business is operated and reported in four segments: Liquor Retail, Cannabis Retail, Cannabis Operations and Investments.
Liquor Retail
SNDL is Canada's largest private sector liquor retailer, operating 170 locations, predominantly in Alberta, under its three retail banners: "Wine and Beyond", "Liquor Depot" and "Ace Liquor".
Cannabis Retail
With its ownership interest in Nova, SNDL is Canada's largest private-sector cannabis retailer, operating 196 locations under its four retail banners: Value Buds, Spiritleaf, Superette, and Firesale Cannabis. SNDL's Cannabis Retail strategy is based on several factors, including the quality of its store locations, the range of products it offers, and the unique experiences it provides customers. Using data and insights from a large volume of monthly transactions enables SNDL to leverage technology and analytics to inform and improve its retail strategy.
On July 25, 2023, SNDL and Nova announced that while all other provincial approvals have been received, the continued review by one provincial regulator has necessitated the extension of the outside date for the closing of the previously-announced strategic partnership (the "Transaction"). SNDL and Nova anticipate that the Transaction will close on or before August 25, 2023, subject to the receipt of regulatory approval and the amendment to certain terms of the Transaction that are mutually satisfactory to SNDL and Nova.
Cannabis Operations
SNDL has a diverse brand portfolio from value to premium, emphasizing premium inhalable formats and a full suite of 2.0 products. With enhanced procurement capabilities, premium cultivation and manufacturing facilities, the Cannabis Operations segment is a key enabler of SNDL's vertical integration strategy.
Investments
Three months ended | Six months ended | ||||
($000s) | 2023 | 2022 | 2023 | 2022 | |
Interest and fee revenue | |||||
Interest revenue from investments at amortized cost | 922 | 818 | 1,928 | 1,813 | |
Interest and fee revenue from investments at Fair | 250 | 543 | 874 | 2,659 | |
Interest revenue from cash | 2,014 | 1,216 | 4,595 | 1,966 | |
Total interest and fee revenue | 3,186 | 2,577 | 7,397 | 6,438 | |
Investment revenue (loss) | |||||
Realized (losses) gains | (48,988) | 265 | (92,792) | 389 | |
Unrealized gains (losses) | 45,182 | (35,338) | 84,100 | (53,172) | |
Total investment revenue/(loss) | (3,806) | (35,073) | (8,692) | (52,783) | |
Share of profit (loss) of equity-accounted investees | (936) | (37,978) | 8,580 | (33,887) | |
Total investment activities | (1,556) | (70,474) | 7,285 | (80,232) |
Liquidity Position
STRATEGIC AND ORGANIZATIONAL UPDATE
SNDL remains focused on building long-term shareholder value through vertical integration, the accretive deployment of cash resources, expansion of its retail distribution network, the further streamlining of the Company's operating structure, and enhanced offerings of high-quality brands within the Liquor Retail, Cannabis Retail and Cannabis Operations segments.
Integration Initiatives
The Company has achieved $18.2 million in annualized cost savings since the Valens acquisition in January 2023. These initiatives surpass the Company's original $10 million cost savings target. Most of the cost savings have been realized through SG&A, public company costs, as well as supply chain consolidation and operational efficiency. By 2024, run-rate synergies are expected to exceed $30 million annually, and proceeds from asset sales are expected to total $9 million.
The integration work has allowed the Company to undertake a comprehensive organizational design update, restructuring certain departments to achieve scale, support growth, and reinforce key initiatives. The organizational design work supports a more efficient structuring of SNDL's shared service teams to realize additional cost savings and enable targeted focus on key initiatives, such as loyalty, e-commerce, increasing market share within owned retail, and manufacturing, cultivation and processing improvements.
The Company's integration initiatives are critical to SNDL's vision of establishing Canada's largest regulated products platform and generating sustainable free cash flow.
SNDL's strategy is predicated on the below key objectives:
This press release is intended to be read in conjunction with the Company's Financial Statements and Notes for the period ended June 30, 2023, and the accompanying Management's Discussion and Analysis ("MD&A"). These reports are available under the Company's profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml.
CONFERENCE CALL
The Company will hold a conference call and webcast at 10:30 a.m. EST (8:30 a.m. MST) on Monday, August 14, 2023.
WEBCAST ACCESS
To access the live webcast of the call, please visit the following link:
https://services.choruscall.ca/links/sndl2023q2.html
REPLAY
A telephone replay will be available for one month. To access the replay, dial:
Canada/USA Toll Free: 1-800-319-6413 or International Toll: +1-604-638-9010
When prompted, enter Replay Access Code: 0323#
The webcast archive will be available for three months via the link provided above.
ABOUT SNDL INC.
SNDL is a public company whose shares are traded on the Nasdaq under the symbol "SNDL."
SNDL is the largest private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, Spiritleaf, and Firesale Cannabis. SNDL is a licensed cannabis producer and one of the largest vertically integrated cannabis companies in Canada specializing in low-cost biomass sourcing, premium indoor cultivation, product innovation, low-cost manufacturing facilities, and a cannabis brand portfolio that includes Top Leaf, Contraband, Citizen Stash, Sundial Cannabis, Palmetto, Bon Jak, Spiritleaf Selects, Versus Cannabis, Value Buds, Vacay, Grasslands and Superette. SNDL's investment portfolio seeks to deploy strategic capital through direct and indirect investments and partnerships throughout the North American cannabis industry.?For more information on SNDL, please go to?https://sndl.com/.
Forward-Looking Information Cautionary Statement
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"), including, but not limited to, statements regarding the Company's operational goals, demand for the Company's products, the Company's ability to achieve profitability or its goal of sustainable, positive gross margin and positive free cash flow,?the development of the legal cannabis industry, performance of the Company's investments, including through the SunStream joint venture, any potential forms of shareholder value creation, the ability to realize expected cost savings and the expansion of product offerings, brand and market share and retail networks, and the closing, integration and realization of expected benefits of, as applicable, the acquisition of The Valens Company, Zenabis and Superette. Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate",?"likely", "outlook", "forecast",?"may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are?made and?are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Please see "Item 3.D.?Risk Factors" in the?Company's annual report on Form 20-F, filed with the Securities and Exchange Commission ("SEC") on April 24, 2023, and the risk factors included in our other SEC filings for?a discussion of the material risk factors that could cause actual results to differ materially from the forward-looking information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether?as a result of?new information, future events or otherwise, except as expressly required by applicable law.
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
Three months ended | Six months ended | |||||||
2023 | 2022 | 2023 | 2022 | |||||
Gross revenue | 257,425 | 227,557 | 470,324 | 247,684 | ||||
Excise taxes | 12,914 | 3,862 | 23,361 | 6,392 | ||||
Net revenue | 244,511 | 223,695 | 446,963 | 241,292 | ||||
Cost of sales | 188,922 | 174,291 | 347,071 | 188,617 | ||||
Inventory impairment and obsolescence | 4,291 | 3,871 | 13,468 | 5,852 | ||||
Gross margin before fair value adjustments | 51,298 | 45,533 | 86,424 | 46,823 | ||||
Change in fair value of biological assets | (1,413) | (388) | (4,948) | 3,302 | ||||
Change in fair value realized through inventory | 2,048 | (2,066) | 2,998 | (3,627) | ||||
Gross margin | 51,933 | 43,079 | 84,474 | 46,498 | ||||
Interest and fee revenue | 3,421 | 2,577 | 7,632 | 6,438 | ||||
Investment loss | (4,020) | (35,073) | (9,189) | (52,783) | ||||
Share of profit (loss) of equity-accounted investees | (936) | (37,978) | 8,580 | (33,887) | ||||
General and administrative | 52,727 | 40,293 | 101,300 | 50,975 | ||||
Sales and marketing | 4,104 | 3,132 | 7,490 | 4,243 | ||||
Research and development | 20 | 390 | 160 | 485 | ||||
Depreciation and amortization | 13,443 | 8,800 | 29,911 | 9,539 | ||||
Share-based compensation | 3,893 | 438 | 6,102 | 4,642 | ||||
Restructuring costs | 4,042 | (882) | 5,578 | (882) | ||||
Asset impairment | 1,658 | 1,850 | 2,465 | 1,850 | ||||
Loss from operations | (29,489) | (81,416) | (61,509) | (104,586) | ||||
Transaction costs | (173) | 7,938 | (2,213) | 1,457 | ||||
Finance costs, net | (2,458) | (26,505) | (7,631) | (26,444) | ||||
Change in estimate of fair value of derivative warrants | 2,240 | 23,656 | 7,042 | 15,356 | ||||
Foreign exchange gain (loss) | (31) | 161 | (194) | 11 | ||||
Gain (loss) on disposition of assets | (77) | 402 | (261) | 402 | ||||
Loss before income tax | (29,988) | (75,764) | (64,766) | (113,804) | ||||
Income tax recovery | ? | 1,791 | ? | 1,791 | ||||
Net loss from continuing operations | (29,988) | (73,973) | (64,766) | (112,013) | ||||
Net loss from discontinued operations | (3,170) | ? | (4,535) | ? | ||||
Net loss | (33,158) | (73,973) | (69,301) | (112,013) | ||||
Equity-accounted investees - share of other | (11,621) | 12,727 | (12,006) | 5,994 | ||||
Gain on translation of foreign operations | (5) | ? | ? | ? | ||||
Comprehensive loss | (44,784) | (61,246) | (81,307) | (106,019) | ||||
Net loss from continuing operations attributable to: | ||||||||
Owners of the Company | (29,350) | (73,301) | (63,553) | (111,205) | ||||
Non-controlling interest | (638) | (672) | (1,213) | (808) | ||||
(29,988) | (73,973) | (64,766) | (112,013) | |||||
Net income (loss) attributable to: | ||||||||
Owners of the Company | (32,520) | (73,301) | (68,088) | (111,205) | ||||
Non-controlling interest | (638) | (672) | (1,213) | (808) | ||||
(33,158) | (73,973) | (69,301) | (112,013) | |||||
Comprehensive income (loss) attributable to: | ||||||||
Owners of the Company | (44,146) | (60,574) | (80,094) | (105,211) | ||||
Non-controlling interest | (638) | (672) | (1,213) | (808) | ||||
(44,784) | (61,246) | (81,307) | (106,019) |
Condensed Consolidated Interim Statement of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
As at | June 30, 2023 | December 31, 2022 | ||
Assets | ||||
Current assets | ||||
Cash and cash equivalents | 185,455 | 279,586 | ||
Restricted cash | 19,456 | 19,338 | ||
Marketable securities | 3,535 | 21,926 | ||
Accounts receivable | 32,661 | 22,636 | ||
Biological assets | 1,330 | 3,477 | ||
Inventory | 160,407 | 127,782 | ||
Prepaid expenses and deposits | 21,792 | 10,110 | ||
Investments | 23,038 | 6,552 | ||
Assets held for sale | 8,391 | 6,375 | ||
Net investment in subleases | 3,656 | 3,701 | ||
459,721 | 501,483 | |||
Non-current assets | ||||
Long-term deposits | 9,766 | 8,584 | ||
Right of use assets | 136,947 | 134,154 | ||
Property, plant and equipment | 181,841 | 143,409 | ||
Net investment in subleases | 18,918 | 19,618 | ||
Intangible assets | 74,446 | 74,885 | ||
Investments | 9,638 | 90,702 | ||
Equity-accounted investees | 532,818 | 519,255 | ||
Goodwill | 147,680 | 67,260 | ||
Total assets | 1,571,775 | 1,559,350 | ||
Liabilities | ||||
Current liabilities | ||||
Accounts payable and accrued liabilities | 62,557 | 48,153 | ||
Lease liabilities | 35,982 | 30,206 | ||
Derivative warrants | 3,960 | 11,002 | ||
102,499 | 89,361 | |||
Non-current liabilities | ||||
Lease liabilities | 136,136 | 139,625 | ||
Other liabilities | 5,252 | 2,709 | ||
Total liabilities | 243,887 | 231,695 | ||
Shareholders' equity | ||||
Share capital | 2,365,845 | 2,292,810 | ||
Warrants | 2,260 | 2,260 | ||
Contributed surplus | 73,636 | 68,961 | ||
Contingent consideration | 2,279 | 2,279 | ||
Accumulated deficit | (1,156,279) | (1,091,999) | ||
Accumulated other comprehensive income | 20,182 | 32,188 | ||
Total shareholders' equity | 1,307,923 | 1,306,499 | ||
Non-controlling interest | 19,965 | 21,156 | ||
Total liabilities and shareholders' equity | 1,571,775 | 1,559,350 |
Condensed Consolidated Interim Statement of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
Three months ended | Six months ended | |||||
2023 | 2022 | 2023 | 2022 | |||
Cash provided by (used in): | ||||||
Operating activities | ||||||
Net loss for the period | (33,158) | (73,973) | (69,301) | (112,013) | ||
Adjustments for: | ||||||
Income tax recovery | ? | (1,791) | ? | (1,791) | ||
Interest and fee revenue | (3,421) | (2,577) | (7,632) | (6,438) | ||
Change in fair value of biological assets | 1,413 | 388 | 4,948 | (3,302) | ||
Share-based compensation | 3,893 | 438 | 6,102 | 4,642 | ||
Depreciation and amortization | 14,674 | 10,538 | 32,933 | 12,977 | ||
Loss (gain) on disposition of assets | 77 | (402) | 261 | (402) | ||
Inventory obsolescence | 4,291 | 3,871 | 13,468 | 5,852 | ||
Finance costs | 2,458 | 26,505 | 7,631 | 26,444 | ||
Change in estimate of fair value of derivative warrants | (2,240) | (23,656) | (7,042) | (15,356) | ||
Unrealized foreign exchange loss (gain) | (72) | 19 | (24) | 35 | ||
Asset impairment | 1,658 | 1,850 | 2,465 | 1,850 | ||
Share of (profit) loss of equity-accounted investees | 936 | 37,978 | (8,580) | 33,887 | ||
Loss on settlement of marketable securities | 48,988 | ? | 92,792 | ? | ||
Unrealized (gain) loss on marketable securities | (44,968) | 35,338 | (83,603) | 53,172 | ||
Additions to marketable securities | ? | (2,899) | ? | (3,500) | ||
Proceeds from settlement of marketable securities | 3,437 | ? | 3,463 | ? | ||
Income distributions from equity-accounted investees | ? | ? | ? | 685 | ||
Interest received | 3,217 | 2,084 | 6,920 | 5,799 | ||
Change in non-cash working capital | (14,193) | (31,584) | (56,755) | (46,434) | ||
Net cash used in operating activities from continuing operations | (13,010) | (17,873) | (61,954) | (43,893) | ||
Net cash provided by operating activities from discontinued operations | 4,167 | ? | 4,314 | ? | ||
Net cash used in operating activities | (8,843) | (17,873) | (57,640) | (43,893) | ||
Investing activities | ||||||
Additions to property, plant and equipment | (1,247) | (3,554) | (2,641) | (4,535) | ||
Additions to intangible assets | (39) | 1 | (56) | (55) | ||
Additions to investments | 125 | 337 | (702) | (14,094) | ||
Additions to equity-accounted investees | (9,443) | (36,880) | (16,989) | (94,200) | ||
Proceeds from disposal of property, plant and equipment | 55 | 4,000 | 137 | 4,000 | ||
Acquisitions, net of cash acquired | ? | ? | 3,695 | (31,149) | ||
Change in non-cash working capital | 1,586 | 294 | 1,127 | 259 | ||
Net cash used in investing activities from continuing operations | (8,963) | (35,802) | (15,429) | (139,774) | ||
Net cash used in investing activities from discontinued operations | ? | ? | ? | ? | ||
Net cash used in investing activities | (8,963) | (35,802) | (15,429) | (139,774) | ||
Financing activities | ||||||
Change in restricted cash | (76) | 2,541 | (118) | 7,607 | ||
Payments on lease liabilities, net | (10,116) | (9,177) | (19,607) | (9,624) | ||
Repurchase of common shares, net of costs | ? | (2,053) | (1,536) | (2,053) | ||
Repayment of long-term debt | ? | ? | ? | (10,000) | ||
Change in non-cash working capital | 200 | 2,170 | 199 | 2,116 | ||
Net cash used in financing activities from continuing operations | (9,992) | (6,519) | (21,062) | (11,954) | ||
Net cash used in financing activities from discontinued operations | ? | ? | ? | ? | ||
Net cash used in financing activities | (9,992) | (6,519) | (21,062) | (11,954) | ||
Change in cash and cash equivalents | (27,798) | (60,194) | (94,131) | (195,621) | ||
Cash and cash equivalents, beginning of period | 213,253 | 422,824 | 279,586 | 558,251 | ||
Cash and cash equivalents, end of period | 185,455 | 362,630 | 185,455 | 362,630 |
SPECIFIED FINANCIAL MEASURES
Certain specified financial measures in this news release are non-IFRS measures. These terms are not defined by IFRS and, therefore, may not be comparable to similar measures provided by other companies. These non-IFRS financial measures should not be considered in isolation or as an alternative for or superior to measures of performance prepared in accordance with IFRS.?These measures are presented and described in order to provide shareholders and potential investors with additional measures in understanding the Company's operating results in the same manner as the management team.
ADJUSTED EBITDA
Adjusted EBITDA is a non-IFRS measure which the Company uses to evaluate its operating performance. Adjusted EBITDA provides information to investors,?analysts,?and others?to aid?in understanding and evaluating the Company's operating results in?a manner similar to its management team. Adjusted EBITDA is defined as net income (loss) from continuing operations before finance costs, depreciation and amortization, accretion expense, income tax recovery and excluding changes in fair value of biological assets, changes in fair value realized through inventory, unrealized foreign exchange gains or losses, unrealized gains or losses on marketable securities, changes in fair value of derivative warrants, share-based compensation expense, asset impairment, gain or loss on disposal of property, plant and equipment, cost of sales non-cash component, inventory impairment (recovery) and obsolescence, restructuring costs and transaction costs. The Company presents both consolidated or total Adjusted EBITDA and Adjusted EBITDA by operating segment.
OPERATING SEGMENTS | ||||||
($000s) | Liquor | Cannabis | Cannabis | Investments | Corporate | Total |
Three months ended June 30, 2023 | ||||||
Net earnings (loss) | 6,714 | 1,221 | (13,831) | (1,917) | (22,175) | (29,988) |
Adjustments | ||||||
Finance costs | 1,490 | 1,111 | (400) | 257 | ? | 2,458 |
Change in estimate of fair value of | ? | ? | ? | ? | (2,240) | (2,240) |
Depreciation and amortization | 8,161 | 3,361 | 650 | ? | 1,271 | 13,443 |
Change in fair value of biological assets | ? | ? | 1,413 | ? | ? | 1,413 |
Change in fair value realized through | ? | ? | (2,048) | ? | ? | (2,048) |
Unrealized foreign exchange (gain) loss | (2) | ? | (70) | ? | ? | (72) |
Unrealized (gain) loss on marketable | ? | ? | 214 | (45,182) | ? | (44,968) |
Realized loss on marketable securities | ? | ? | ? | 49,093 | ? | 49,093 |
Share-based compensation | ? | 15 | ? | ? | 3,878 | 3,893 |
Asset impairment | ? | 458 | 1,200 | ? | ? | 1,658 |
Loss (gain) on disposition of PP&E | ? | 5 | 72 | ? | ? | 77 |
Cost of sales non-cash component (1) | ? | ? | 969 | ? | ? | 969 |
Inventory impairment (recovery) and | ? | ? | 4,291 | ? | ? | 4,291 |
Restructuring costs | ? | ? | 1,282 | ? | 2,760 | 4,042 |
Transaction costs | ? | ? | ? | ? | 173 | 173 |
Adjusted EBITDA | 16,363 | 6,171 | (6,258) | 2,251 | (16,333) | 2,194 |
(1) Cost of sales non-cash component is comprised of depreciation expense |
OPERATING SEGMENTS | ||||||
($000s) | Liquor | Cannabis | Cannabis | Investments | Corporate | Total |
Three months ended June 30, 2022 | ||||||
Net earnings (loss) | 8,379 | 447 | (8,036) | (90,487) | 15,724 | (73,973) |
Adjustments | ||||||
Finance costs | 2,874 | 1,070 | 195 | 22,305 | 61 | 26,505 |
Change in estimate of fair value of | ? | (56) | ? | ? | (23,600) | (23,656) |
Depreciation and amortization | 5,315 | 3,370 | ? | ? | 115 | 8,800 |
Income tax recovery | ? | ? | ? | (1,791) | ? | (1,791) |
Change in fair value of biological assets | ? | ? | 388 | ? | ? | 388 |
Change in fair value realized through | ? | ? | 2,066 | ? | ? | 2,066 |
Unrealized foreign exchange (gain) loss | 9 | ? | 10 | ? | ? | 19 |
Unrealized (gain) loss on marketable | ? | ? | ? | 35,338 | ? | 35,338 |
Share-based compensation | ? | (180) | ? | ? | 618 | 438 |
Asset impairment | ? | ? | 1,850 | ? | ? | 1,850 |
Loss (gain) on disposition of PP&E | 35 | 15 | (452) | ? | ? | (402) |
Cost of sales non-cash component (1) | ? | ? | 3,440 | ? | ? | 3,440 |
Inventory impairment (recovery) and | ? | ? | 3,871 | ? | ? | 3,871 |
Restructuring costs | ? | ? | ? | (882) | ? | (882) |
Transaction costs | ? | ? | ? | ? | (7,938) | (7,938) |
Adjusted EBITDA | 16,612 | 4,666 | 3,332 | (35,517) | (15,020) | (25,927) |
(1) Cost of sales non-cash component is comprised of depreciation expense |
SOURCE Sundial Growers Inc.
These press releases may also interest you
|